These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 37129893)
1. Assessment of Tumor Mutational Burden and Outcomes in Patients With Diverse Advanced Cancers Treated With Immunotherapy. Aggarwal C; Ben-Shachar R; Gao Y; Hyun SW; Rivers Z; Epstein C; Kaneva K; Sangli C; Nimeiri H; Patel J JAMA Netw Open; 2023 May; 6(5):e2311181. PubMed ID: 37129893 [TBL] [Abstract][Full Text] [Related]
2. Association of Survival and Immune-Related Biomarkers With Immunotherapy in Patients With Non-Small Cell Lung Cancer: A Meta-analysis and Individual Patient-Level Analysis. Yu Y; Zeng D; Ou Q; Liu S; Li A; Chen Y; Lin D; Gao Q; Zhou H; Liao W; Yao H JAMA Netw Open; 2019 Jul; 2(7):e196879. PubMed ID: 31290993 [TBL] [Abstract][Full Text] [Related]
3. Integration of comprehensive genomic profiling, tumor mutational burden, and PD-L1 expression to identify novel biomarkers of immunotherapy in non-small cell lung cancer. Shi Y; Lei Y; Liu L; Zhang S; Wang W; Zhao J; Zhao S; Dong X; Yao M; Wang K; Zhou Q Cancer Med; 2021 Apr; 10(7):2216-2231. PubMed ID: 33655698 [TBL] [Abstract][Full Text] [Related]
4. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104 [TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer. Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176 [TBL] [Abstract][Full Text] [Related]
6. Association of TP53 mutations with response and longer survival under immune checkpoint inhibitors in advanced non-small-cell lung cancer. Assoun S; Theou-Anton N; Nguenang M; Cazes A; Danel C; Abbar B; Pluvy J; Gounant V; Khalil A; Namour C; Brosseau S; Zalcman G Lung Cancer; 2019 Jun; 132():65-71. PubMed ID: 31097096 [TBL] [Abstract][Full Text] [Related]
7. Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel. Wang Z; Duan J; Cai S; Han M; Dong H; Zhao J; Zhu B; Wang S; Zhuo M; Sun J; Wang Q; Bai H; Han J; Tian Y; Lu J; Xu T; Zhao X; Wang G; Cao X; Li F; Wang D; Chen Y; Bai Y; Zhao J; Zhao Z; Zhang Y; Xiong L; He J; Gao S; Wang J JAMA Oncol; 2019 May; 5(5):696-702. PubMed ID: 30816954 [TBL] [Abstract][Full Text] [Related]
8. Clinical Implications of Circulating Tumor DNA Tumor Mutational Burden (ctDNA TMB) in Non-Small Cell Lung Cancer. Chae YK; Davis AA; Agte S; Pan A; Simon NI; Iams WT; Cruz MR; Tamragouri K; Rhee K; Mohindra N; Villaflor V; Park W; Lopes G; Giles FJ Oncologist; 2019 Jun; 24(6):820-828. PubMed ID: 30867242 [TBL] [Abstract][Full Text] [Related]
9. Tumor mutational burden assessed by targeted NGS predicts clinical benefit from immune checkpoint inhibitors in non-small cell lung cancer. Alborelli I; Leonards K; Rothschild SI; Leuenberger LP; Savic Prince S; Mertz KD; Poechtrager S; Buess M; Zippelius A; Läubli H; Haegele J; Tolnay M; Bubendorf L; Quagliata L; Jermann P J Pathol; 2020 Jan; 250(1):19-29. PubMed ID: 31471895 [TBL] [Abstract][Full Text] [Related]
10. Association of High Tumor Mutation Burden in Non-Small Cell Lung Cancers With Increased Immune Infiltration and Improved Clinical Outcomes of PD-L1 Blockade Across PD-L1 Expression Levels. Ricciuti B; Wang X; Alessi JV; Rizvi H; Mahadevan NR; Li YY; Polio A; Lindsay J; Umeton R; Sinha R; Vokes NI; Recondo G; Lamberti G; Lawrence M; Vaz VR; Leonardi GC; Plodkowski AJ; Gupta H; Cherniack AD; Tolstorukov MY; Sharma B; Felt KD; Gainor JF; Ravi A; Getz G; Schalper KA; Henick B; Forde P; Anagnostou V; Jänne PA; Van Allen EM; Nishino M; Sholl LM; Christiani DC; Lin X; Rodig SJ; Hellmann MD; Awad MM JAMA Oncol; 2022 Aug; 8(8):1160-1168. PubMed ID: 35708671 [TBL] [Abstract][Full Text] [Related]
11. Use of targeted next generation sequencing to characterize tumor mutational burden and efficacy of immune checkpoint inhibition in small cell lung cancer. Ricciuti B; Kravets S; Dahlberg SE; Umeton R; Albayrak A; Subegdjo SJ; Johnson BE; Nishino M; Sholl LM; Awad MM J Immunother Cancer; 2019 Mar; 7(1):87. PubMed ID: 30922388 [TBL] [Abstract][Full Text] [Related]
12. Predictive Value of Combining Biomarkers for Clinical Outcomes in Advanced Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Inhibitors. Kao C; Powers E; Wu Y; Datto MB; Green MF; Strickler JH; Ready NE; Zhang T; Clarke JM Clin Lung Cancer; 2021 Nov; 22(6):500-509. PubMed ID: 33972172 [TBL] [Abstract][Full Text] [Related]
13. Genomic scoring to determine clinical benefit of immunotherapy by targeted sequencing. Kim HS; Cha H; Kim J; Park WY; Choi YL; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH Eur J Cancer; 2019 Oct; 120():65-74. PubMed ID: 31493723 [TBL] [Abstract][Full Text] [Related]
14. Prevalence of PDL1 Amplification and Preliminary Response to Immune Checkpoint Blockade in Solid Tumors. Goodman AM; Piccioni D; Kato S; Boichard A; Wang HY; Frampton G; Lippman SM; Connelly C; Fabrizio D; Miller V; Sicklick JK; Kurzrock R JAMA Oncol; 2018 Sep; 4(9):1237-1244. PubMed ID: 29902298 [TBL] [Abstract][Full Text] [Related]
15. Comparative Effectiveness of Immune Checkpoint Inhibitors vs Chemotherapy by Tumor Mutational Burden in Metastatic Castration-Resistant Prostate Cancer. Graf RP; Fisher V; Weberpals J; Gjoerup O; Tierno MB; Huang RSP; Sayegh N; Lin DI; Raskina K; Schrock AB; Severson E; Haberberger JF; Ross JS; Creeden J; Levy MA; Alexander BM; Oxnard GR; Agarwal N JAMA Netw Open; 2022 Mar; 5(3):e225394. PubMed ID: 35357449 [TBL] [Abstract][Full Text] [Related]
16. PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. Sabari JK; Leonardi GC; Shu CA; Umeton R; Montecalvo J; Ni A; Chen R; Dienstag J; Mrad C; Bergagnini I; Lai WV; Offin M; Arbour KC; Plodkowski AJ; Halpenny DF; Paik PK; Li BT; Riely GJ; Kris MG; Rudin CM; Sholl LM; Nishino M; Hellmann MD; Rekhtman N; Awad MM; Drilon A Ann Oncol; 2018 Oct; 29(10):2085-2091. PubMed ID: 30165371 [TBL] [Abstract][Full Text] [Related]
17. Association of Machine Learning-Based Assessment of Tumor-Infiltrating Lymphocytes on Standard Histologic Images With Outcomes of Immunotherapy in Patients With NSCLC. Rakaee M; Adib E; Ricciuti B; Sholl LM; Shi W; Alessi JV; Cortellini A; Fulgenzi CAM; Viola P; Pinato DJ; Hashemi S; Bahce I; Houda I; Ulas EB; Radonic T; Väyrynen JP; Richardsen E; Jamaly S; Andersen S; Donnem T; Awad MM; Kwiatkowski DJ JAMA Oncol; 2023 Jan; 9(1):51-60. PubMed ID: 36394839 [TBL] [Abstract][Full Text] [Related]
18. Association of Programmed Cell Death Ligand 1 Expression Status With Receipt of Immune Checkpoint Inhibitors in Patients With Advanced Non-Small Cell Lung Cancer. Leapman MS; Presley CJ; Zhu W; Soulos PR; Adelson KB; Miksad RA; Boffa DJ; Gross CP JAMA Netw Open; 2020 Jun; 3(6):e207205. PubMed ID: 32511721 [TBL] [Abstract][Full Text] [Related]
19. STK11 and KEAP1 mutations in non-small cell lung cancer patients: Descriptive analysis and prognostic value among Hispanics (STRIKE registry-CLICaP). Cordeiro de Lima VC; Corassa M; Saldanha E; Freitas H; Arrieta O; Raez L; Samtani S; Ramos M; Rojas C; Burotto M; Chamorro DF; Recondo G; Ruiz-Patiño A; Más L; Zatarain-Barrón L; Mejía S; Nicolas Minata J; Martín C; Bautista Blaquier J; Motta Guerrero R; Aliaga-Macha C; Carracedo C; Ordóñez-Reyes C; Garcia-Robledo JE; Corrales L; Sotelo C; Ricaurte L; Santoyo N; Cuello M; Jaller E; Rodríguez J; Archila P; Bermudez M; Gamez T; Russo A; Viola L; Malapelle U; de Miguel Perez D; Rolfo C; Rosell R; Cardona AF Lung Cancer; 2022 Aug; 170():114-121. PubMed ID: 35753125 [TBL] [Abstract][Full Text] [Related]
20. First-Line Nivolumab Plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer (CheckMate 568): Outcomes by Programmed Death Ligand 1 and Tumor Mutational Burden as Biomarkers. Ready N; Hellmann MD; Awad MM; Otterson GA; Gutierrez M; Gainor JF; Borghaei H; Jolivet J; Horn L; Mates M; Brahmer J; Rabinowitz I; Reddy PS; Chesney J; Orcutt J; Spigel DR; Reck M; O'Byrne KJ; Paz-Ares L; Hu W; Zerba K; Li X; Lestini B; Geese WJ; Szustakowski JD; Green G; Chang H; Ramalingam SS J Clin Oncol; 2019 Apr; 37(12):992-1000. PubMed ID: 30785829 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]